By
Drug Target Review2024-06-04T12:30:07
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-22T13:04:00Z
2026-06-19T08:26:00Z
2026-06-17T12:40:00Z
2023-05-03T15:39:23
Sponsored by BPS Bioscience
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2025-05-14T14:30:00
Sponsored by Abzena
2026-06-02T15:00:00 2026-06-02T16:00:00
Sponsored by Danaher Life Sciences
2024-02-08T11:07:39
Sponsored by Samplix ApS
2024-01-09T09:30:19
Sponsored by Sartorius
Site powered by Webvision Cloud